I have obtained a copy of the Solymos article. Here are what I feel are the salient points:
1) As I noted in an earlier post, the control values are very similar to those reported a year earlier by Segura (Monfort). Though there is some variability in levels among individual subjects, none of the values reaches the very high levels seen after transfusion. In this respect, this report does not support other studies that have found very high levels in some controls. However, this study apparently simply took a single urine sample from each control, and did not consider possible variation over time. Other studies have analyzed several urine samples from subjects taken on different days or different times of the same day, and have also utilized an approach in which all urine excreted over a period of time was analyzed.
If Contador or some other rider were forced to defend elevated values, this would be a key point to make.
2) Also in agreement with Segura, Solymos et al. found enormous variability in DEHP metabolite levels in transfused patients. Part of this is due to the time after transfusion urine was obtained for analysis. Generally, the sooner the better. Solymos analyzed several samples at 6 or even 5 hours after transfusion and these generally exhibited the highest levels. This has obvious implications for any test. If an athlete is not tested very soon after transfusion, metabolites levels drop rapidly and soon may not be clearly distinguishable from controls.
The highest values appear within 6 hours, so a lot of dopers might avoid a positive just by avoiding being tested for a few hours after transfusion.
3) Much of the variability, though, is found between individual subjects. One subject had values of one metabolite 5-10x higher than that of some other transfused subjects. This again agrees with what Segura’s group found. This might be due to the amount of blood transfused, the length of time of transfusion, the composition of the transfusing equipment, etc.
I suspect that if dopers transfused a relatively small amount of blood, in a relatively short amount of time, they would reduce their metabolite levels. As I discussed here last summer, another way to foil the test would be to rinse out the blood bag and other plastic equipment, leaching out some of the DEHP.
4) One of the metabolites, MEHP, does not appear useful for the test. In some transfused subjects, levels of this metabolite were not higher or much higher than many control values. Segura found a few controls with very low levels of all metabolites, and I suspect if Solymos had studied more transfused subjects, they would have found the same thing.
As I think Ferm noted earlier, the authors conclude:
It is emphasized that this assay presents additional data in
the interpretation of the biological passport and it is not
intended to be used separately to proof for blood doping.